LA JOLLA PHARMACEUTICAL CO Form 8-K November 06, 2003

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 6, 2003

LA JOLLA PHARMACEUTICAL COMPANY

(Exact Name of Registrant as Specified in Charter)		
Delaware	0-24274	33-0361285
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
	6455 Nancy Ridge Drive	
	San Diego, California 92121	
(Ad	Idress of Principal Executive Offices, Including Zip Cod	le)
Regist	erant s telephone number, including area code: (858)452	2-6600

TABLE OF CONTENTS

Item 12. Results of Operations and Financial Condition.

SIGNATURES

EXHIBIT 99.1

Table of Contents

Item 12. Results of Operations and Financial Condition.

On November 6, 2003, La Jolla Pharmaceutical Company issued a press release announcing the financial results for its third fiscal quarter ended September 30, 2003. A copy of this press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

The information in this Form 8-K and the exhibit attached hereto and incorporated herein shall not be deemed filed for purposes of the Securities Exchange Act of 1934, as amended (the Exchange Act), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 6, 2003 LA JOLLA PHARMACEUTICAL COMPANY

By: /s/ Steven B. Engle

Steven B. Engle Chairman of the Board and Chief Executive Officer

Table of Contents

EXHIBIT INDEX

Exhibit Number	Description of Exhibit
99.1	Press Release (furnished pursuant to Item 12 of Form 8-K)